Research programme: anti-RANKL therapeutics - Pharmexa

Drug Profile

Research programme: anti-RANKL therapeutics - Pharmexa

Alternative Names: AutoVac RANKL vaccine - Pharmexa; ME 107; Osteoporosis vaccine - Pharmexa; PX 107; PX 107 RANKL AutoVac; RANKL AutoVac; RANKL vaccine - Pharmexa

Latest Information Update: 25 Jun 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmexa
  • Class Vaccines
  • Mechanism of Action Bone resorption factor inhibitors; Immunostimulants; Osteoclast inhibitors; RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bone disorders; Osteoporosis

Most Recent Events

  • 22 Jun 2009 Affitech AS has merged with Pharmexa to form Affitech A/S
  • 27 Feb 2008 Suspended - Preclinical for Bone disorders in Denmark (Parenteral)
  • 27 Feb 2008 Suspended - Preclinical for Osteoporosis in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top